Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMO

Title: Taletrectinib Across Key Subgroups in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From TRUST-I and TRUST-II

Presenter: Hidetoshi Hayashi, Kindai University Faculty of Medicine, Osaka, Japan

Date: Tuesday, September 15, 2026 

Session Time: 9:30-11:00 a.m. KST

Title: Updated Efficacy and Safety of Taletrectinib in Patients with Advanced ROS1+ Non-Small Cell Lung Cancer (NSCLC) After Prior Entrectinib Exposure: Results from the Global TRUST-II Study

Presenter: Maurice Pérol, Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France

Date: Monday, October 26, 2026

Session Time: 12:00-12:45 p.m. CEST